http://rdf.ncbi.nlm.nih.gov/pubchem/patent/HR-P20090394-T1
Outgoing Links
| Predicate | Object |
|---|---|
| assignee | http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_a7f82940e47ba7a1188f8e2ffca55e0f |
| classificationCPCInventive | http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07D487-14 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P25-28 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P43-00 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P25-26 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P25-24 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P25-14 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P9-10 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P25-18 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P25-16 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P25-02 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P25-00 |
| classificationIPCInventive | http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P25-16 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C07D487-14 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K31-519 |
| filingDate | 2009-07-10-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| inventor | http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_ce4e7516e8f928cbcb8fb73e451e87de http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_c31bdd459a9721671bdac1e38eda917d http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_afabe4132e4fc910f8841120eca5000d http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_6cabc765bf3c49b959b63d0a7d996af7 http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_33ef17ce1b98353cf5d735a3907eec57 http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_8e8eb3ce76bf3b12a3f2ce93b5f7780c http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_e5cd896d02f0a225e704543422bea06d |
| publicationDate | 2009-08-31-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationNumber | HR-P20090394-T1 |
| titleOfInvention | 2-ALKINYL- AND 2-ALKENYLPYRAZOLO- [4,3-e] -1,2,4-TRIAZOLO- [1,5-c] -PYRIMIDINE ANTAGONISTS OF ADENOSINE RECEPTOR A2A |
| abstract | A compound of structural formula or a pharmaceutically acceptable salt thereof, wherein R is R 1, R 2, R 3, R 4 and R 5 are independently selected from the group consisting of H, alkyl and alkoxyalkyl; R6 is alkyl, hydroxyalkyl or -CH2F; R7, R8 and R9 are independently selected from the group consisting of H, alkyl, alkoxy, alkylthio, alkoxyalkyl, halogen and -CF3; Z is R10-aryl, R10-heteroaryl or R10 is 1 to 5 substituents independently selected from the group consisting of hydrogen, alkyl, alkenyl, hydroxy, alkoxy, hydroxyalkyl, hydroxy-alkoxy, alkoxyalkyl, alkoxyalkoxy, alkoxy-alkoxy-alkyl-, (di-alkoxy) -alkyl, (hydroxy) -alkoxyalkyl, R15-cycloalkyl, R15-cycloalkylalkyl, cycloalkyl , cycloalkyl-O-alkoxy, alkyl-SO2-, alkyl-SO-, halo, -CN, cyanoalkyl, -CHF2, -CF3, -OCHF2, -OCF3, -C (O) R13, -O-alkylene-C ( O) OR13,? C (O) O-alkyl, -N (R11) (R12), N (R11) (R12) -alkyl, N (R11) (R12) -alkoxy, -C (O) N ) (R16), R11-heteroaryl, R15-heterocycloalkyl, R15-heterocycloalkyl-alkyl, R15-heterocycloalkyl-alkoxy, R15-heterocycloalkyloxy, CF3-alkylene-O-alkyl, CF3-hydroxyalkyl, (CF3) (hydroxy) alkoxy, cyano -alkoxy, -alkylene-C (O) -O-alkyl, -SO2-N (alkyl) 2, (cycloalkyl) hydroxyalkyl, (hydroxyalkyl) alkoxy, (dihydroxy) alkyl, (dihydroxy) alkoxy,? C (= NOR17) -alki or -C (= NOR17) -CF3, or two R10 groups on adjacent ring carbon atoms together form -O-CH2-O-, -O- (CH2) 2-O-,? CH2-O- (CH2) 2 -O-, -O- (CH2) 2-, - (CH2) 3-O-, -O- (CH2) 3-O-, - (CH2) 3-, wherein the ring formed by two substituents R10 and two atoms the carbon in the ring to which they are attached is substituted with R16, or two groups of R10 on adjacent ring carbon atoms together form -N (R11) -C (O) -O-, -N (R11) -C (O) -S -, |
| priorityDate | 2003-04-23-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| type | http://data.epo.org/linked-data/def/patent/Publication |
Incoming Links
Total number of triples: 35.